Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

NCT01864018 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT01864018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01864018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Completed
Start date
August 20, 2013
Completion date
September 9, 2023
Enrollment
87 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis, plasma cell myeloma